Recent molecular profiling revealed that tumors with higher immune signatures showed a trend toward improved OS with the encorafenib, binimetinib, and cetuximab combination.
← all excerpts
Unraveling <i>BRAF</i> alterations: molecular insights to circumvent therapeutic resistance across cancer types.
1
—
—